The Australia-China Life Sciences Partnership Program aims to increase awareness and opportunities for communication, collaboration and commercialisation between the life sciences sectors in Australia and China.
The project will take a multi-level approach delivering high quality, collaborative research and industry projects as well as valuable data analytics on commercial engagement between the two countries. Representatives from the consortium partners will impart their in-market knowledge and expertise to develop an interactive online platform, capability development training program and the organisation of a bilateral symposium (either in Australia or China).
The program will increase the capability of Australian life sciences sector to engage with Chinese investors and partners with the aim to benefit early-stage start-ups through seed funding and SMEs seeking growth via access to the China market.
Visit AusBiotech's website for more information.
Listen to our podcast episode, where our CEO Dr Dan Grant gives us an on-the-ground report from AusBiotech's Asian Investment Series.
|Consortium members||Asialink Business, China BlueSky Partners, FB Rice, KPMG, King & Wood Mallesons, Therapeutic Innovation Australia|
|Project duration||February 2018 - February 2020|
|Contact||Dr Claretta D'Souza, AusBiotech - firstname.lastname@example.org|